Which mutual funds hold Sun Pharmaceutical is a critical question for retail investors seeking to understand their portfolio exposure to India’s leading pharmaceutical company. Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA), currently trading at Rs.1,787.5, commands significant attention from mutual fund managers across equity schemes, with the stock being a core holding in healthcare-focused funds, large-cap diversified portfolios, and passive index funds tracking Nifty and Sensex. Understanding which mutual funds hold Sun Pharmaceutical helps investors avoid unintended concentration risk, assess fund manager conviction, and make informed decisions about their SIP investments in pharmaceutical and healthcare-oriented schemes.
| Parameter | Details |
|---|---|
| Current Price | Rs.1,787.5 |
| Day Range | Rs.1,773.5 – Rs.1,803.5 |
| 52-Week Range | Rs.1,548 – Rs.1,916.6 |
| Volume | 7,52,812 shares |
| Sector | Pharmaceuticals |
| Today’s Movement | +0.3% |
Why Knowing Your MF Exposure to Sun Pharmaceutical Matters
Understanding which mutual funds hold Sun Pharmaceutical directly impacts your portfolio diversification strategy. Many SIP investors unknowingly accumulate excessive exposure to single stocks through multiple fund holdings. Moreover, tracking fund manager positions in quality stocks like SUNPHARMA reveals institutional confidence levels.
Sun Pharmaceutical represents India’s largest pharmaceutical company by market capitalization. The stock features prominently in multiple benchmark indices and sectoral classifications. Consequently, your mutual fund portfolio likely contains SUNPHARMA exposure across several schemes.
Furthermore, knowing your Sun Pharmaceutical exposure helps during portfolio rebalancing exercises. If you already hold the stock directly, additional MF exposure might create concentration risk. Therefore, investors must regularly audit their indirect equity holdings through mutual fund portfolios.
Types of Funds That Typically Hold Sun Pharmaceutical
Several categories of mutual funds maintain positions in Sun Pharmaceutical based on their investment mandates. Healthcare and pharma sectoral funds naturally hold significant SUNPHARMA allocations. Additionally, large-cap and multi-cap funds include this pharmaceutical giant in their portfolios.
Passive index funds tracking Nifty 50, Sensex, and Nifty Pharma hold Sun Pharmaceutical proportionally. These funds mechanically replicate index weights without active selection. Meanwhile, active fund managers exercise discretion in determining SUNPHARMA allocation percentages.
Flexi-cap and focused funds also frequently feature Sun Pharmaceutical among top holdings. ESG funds sometimes include SUNPHARMA based on governance and sustainability metrics. As a result, investors running SIPs across multiple categories likely hold overlapping Sun Pharmaceutical exposure.
| Fund Category | Typical SUNPHARMA Holding | Rationale |
|---|---|---|
| Pharma Sectoral Funds | 8-15% of portfolio | Largest pharma company, mandatory holding |
| Nifty 50 Index Funds | 2-3% of portfolio | Index constituent with proportional weight |
| Large Cap Funds | 1-4% of portfolio | Quality large-cap with stable fundamentals |
| Multi Cap Funds | 1-3% of portfolio | Diversification across market segments |
| Flexi Cap Funds | 0-5% of portfolio | Fund manager discretion based on conviction |
| Focused Funds | 3-7% of portfolio | High-conviction concentrated portfolios |
Nifty and Sensex Index Fund Weightage
Sun Pharmaceutical holds membership in both Nifty 50 and BSE Sensex indices. Index funds tracking these benchmarks automatically include SUNPHARMA at prescribed weights. Therefore, investors in passive strategies gain mandatory exposure to this pharmaceutical stock.
The weightage fluctuates based on free-float market capitalization and index rebalancing exercises. Currently, Sun Pharmaceutical represents approximately 2-3% of Nifty 50 composition. Similarly, Sensex index funds maintain proportional SUNPHARMA holdings based on the 30-stock benchmark.
Additionally, Nifty Pharma index funds carry significantly higher Sun Pharmaceutical allocations. This sectoral index concentrates exclusively on pharmaceutical companies. Consequently, SUNPHARMA weightage in Nifty Pharma funds ranges between 15-20% of total portfolio value.
Active Fund Manager Conviction Explained
Active fund managers demonstrate conviction through position sizing in quality stocks like Sun Pharmaceutical. Overweight positions indicate strong bullish sentiment and research backing. Conversely, underweight allocations signal caution or preference for alternative pharmaceutical stocks.
Fund managers assess Sun Pharmaceutical based on multiple parameters including earnings growth, export potential, and product pipeline. They compare SUNPHARMA against peers like Dr. Reddy’s, Cipla, and Lupin. Moreover, managers evaluate regulatory environments across key markets including the United States and Europe.
Furthermore, tracking changes in fund manager holdings provides valuable insights. Increasing stakes suggest growing confidence in SUNPHARMA’s prospects. Meanwhile, position trimming might indicate profit booking or concerns about valuation levels.
- Research-driven allocation: Fund managers conduct extensive fundamental analysis before position sizing
- Benchmark comparison: Holdings evaluated relative to index weights and category averages
- Risk management: Position limits prevent excessive concentration in single stocks
- Performance attribution: SUNPHARMA holdings contribute to overall fund returns
- Peer preference: Managers choose between multiple pharmaceutical stocks based on conviction
How to Check If Your SIP Holds Sun Pharmaceutical
Investors can verify Sun Pharmaceutical exposure through multiple channels and digital platforms. The